Journals / Türk Üroloji Dergisi/Turkish Journal of Urology / 2010 / Cilt: 36 - Sayı: 2

Mikroskopik hematüri ile mesane kanserinin ilişkisi: Bugün için kullanılan tanı yöntemleri güvenilir mi?

The relationship between microscopic hematuria and bladder cancer: Are currently available diagnostic methods reliable?

Pages
103–107
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overall, 10.7% (n=16) of patients had pathological diagnosis of bladder cancer, whereas 89.5% of the study population had no etiology for microhematuria.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study aimed to evaluate the sensitivity and specificity of radiological diagnostic methods, urinary biomarkers and urine cytology for patients with microscopic hematuria in the diagnosis of bladder cancer.
📊
Key Findings & Data:Materials and methods: A total of 150 patients with the initial diagnosis of microscopic hematuria were included in the study.
💡
Conclusion & Impact:Overall, 10.7% (n=16) of patients had pathological diagnosis of bladder cancer, whereas 89.5% of the study population had no etiology for microhematuria.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: This study aimed to evaluate the sensitivity and specificity of radiological diagnostic methods, urinary biomarkers and urine cytology for patients with microscopic hematuria in the diagnosis of bladder cancer. Materials and methods: A total of 150 patients with the initial diagnosis of microscopic hematuria were included in the study. Patients were prospectively evaluated in terms of urinary symptomatology, physical examination, smoking habits, intravenous pyelography (IVP), abdominal ultrasonography (USG), Nuclear Matrix Protein 22 (NMP22), urine cytology and NMP22 BladderChek® test. The cut-off point for NMP22 test was accepted as 10 U/mL. Results: Mean age of the study population was 49.8±10.79 years with a male to female ratio of 1.08 (78/72). Overall, 10.7% (n=16) of patients had pathological diagnosis of bladder cancer, whereas 89.5% of the study population had no etiology for microhematuria. IVP was considered as the most sensitive and specific test in the diagnosis of bladder cancer. However, voided urine cytology was the least sensitive test, although it has the same specificity with IVP. The best sensitivity and specificity values were demonstrated when NMP22 and abdominal USG were used in double-test combinations. Conclusion: In microscopic hematuria, the combination of radiological methods with tumor markers such as NMP22 BladderChek® test, provides 100% sensitivity, and protects nearly half of cases from unnecessary cystoscopies.

Özet

Amaç: Bu çalışmada, mikroskobik hematürisi olan hastalarda mesane kanseri tanısında radyolojik tanı metodları, idrar tümör belirleyicileri ve idrar sitolojisinin duyarlılık ve özgüllüğünün değerlendirilmesi amaçlanmıştır. Gereç ve yöntem: İlk inceleme sonrası mikroskobik hematüri tanısı alan toplam 150 hasta çalışmaya alınmıştır. Hastalar prospektif olarak idrar semptomatolojisi ve sigara alışkanlığı yönünden sorgulanarak fizik muayene, intravenöz pyelografi (IVP), batın ultrasonografisi (USG), Nükleer Matriks protein 22 (NMP22), idrar sitolojisi ve NMP22 BladderChek® testleri ile değerlendirildi. NMP22 testi için eşik değer olarak 10 U/mL alındı. Bulgular: Yaş ortalaması 49.8±10.79 yıl olup çalışma grubundaki erkek/kadın oranı 1.08 oranında tespit edilmiştir (78/72). Hastaların %10.7 sinde (n=16) alınan biyopsi sonucunda mesane kanseri tespit edilirken %89.5’inde mikrohematüri için bir sebep bulunmamıştır. IVP, mesane kanseri teşhisinde en duyarlı ve özgül test olarak bulunmuştur. Ancak idrar işeme sitolojisi IVP ile aynı özgüllük değerine sahip olmasına rağmen en az duyarlı test olarak izlenmiştir. İkili test kombinasyonlarında, en yüksek duyarlılık ve özgüllük değerleri NMP22 ve batın USG testleriyle sağlanmıştır. Sonuç: Mikroskobik hematüride radyolojik tanı yöntemlerinin, NMP22 BladderChek® testi gibi tümör belirteçleriyle kombine kullanılması %100 duyarlılık sağlarken hastaların yaklaşık yarısını gereksiz sistoskopiden korumaktadır.

🔖

Cite This Article

IRKILATA, L., SÖZEN, S., TOKGÖZ, H., KORDAN, Y., KIRAÇ, M., ONARAN, M., ALKİBAY, T., BOZKIRLI, İ. (2010). Mikroskopik hematüri ile mesane kanserinin ilişkisi: Bugün için kullanılan tanı yöntemleri güvenilir mi?. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 36 - Sayı: 2, 103–107. https://ajindex.com/articles/328913

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Zaak D, Karl A, Knüchel R, Stepp H, Hartmann A, Reich O, et al. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy. BJU Int 2005
  2. PMID: 16001963 2. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001
  3. Grossfeld GD, Carroll PR. Evaluation of asymptomatic microscopic hematuria Urol Clin North Am 1998
  4. PMID: 10026773 4. Golin AL, Howard RS. Asymptomatic microscopic hematuria. J Urol 1980
  5. PMID: 7431504 5. Carson CC, Segura JW, Greenee LF. Clinical importance of microhematuria. JAMA 1979
  6. PMID: 758513 6. Fey EG, Penman S. Nuclear matrix proteins reflect cell type of origin in cultured human cells. Proc Natl Acad Sci USA 1998
  7. PMID: 3277168 PMCID: PMC279495 7. Howard RS, Golin AL. Long term follow up of asymptomatic microhematuria. J Urol 1991
  8. PMID: 1988725 8. Britton JP, Dowell AC, Whelan P, Harris CM. A community study of bladder cancer screening by the detection of occult urinary bleeding. J Urol 1992
  9. PMID: 1988725 9. Ritchie CD, Bevan EA, Collier SJ. Importance of occult hematuria found at screening. Br Med J 1986
  10. PMID: 3081223 PMCID: PMC1339660 10. Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, Willsey LW, Diney C, Grossman HB, et al. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 1998
  11. PMID: 9649246 11. Ramakumar S, Bhuiyan J, Besse JA, Roberts SG, Wollan PC, Blute ML, et al. Comparison of screening methods in the detection of bladder cancer J Urol 1999
  12. PMID: 9915409 12. Del-Nero A, Esposito N, Curro A, Biasoni D, Montanari E, Mangiarotti B, et al. Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer:Comparison with urinary cytology and BTA test. Eur Urol 1999
  13. PMID: 9933801 13. Lahme S, Bichler KH, Feil G, Krause S. Comparison of cytology and NMP22 for the detection and follow up of bladder cancer. Urol Int 2001
  14. PMID: 11223747 14. Sözen S, Biri H, Sınık Z, Küpeli B, Alkibay T, Bozkırlı İ. Comparison of the NMP22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder. Eur Urol 1999
  15. PMID: 10450007 15. Sharma S, Zippe C, Pandrangi L, Nelson D, Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 1999
  16. PMID: 10379739 16. Khadra MH, Picka